Eikon was founded ​in 2019 by Chemistry Nobel Prize winner Eric Betzig, along with Xavier Darzacq, Luke Lavis and Robert ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

By Michael Erman and Mariam Sunny Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia ...

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Global therapeutic portfolio spans human and animal health Oncology and vaccine franchises anchor clinical presence ...

Merck & Co forecasts lower 2026 sales and profits due to post-patent challenges for key drugs like Januvia, despite strong performance from Keytruda. The company's proactive measures include ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...